Literature DB >> 26705385

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis.

Alexander Niessner1, Juan Tamargo2, João Morais3, Lorenz Koller1, Sven Wassmann4, Steen Elkjær Husted5, Christian Torp-Pedersen6, Keld Kjeldsen7,8, Basil S Lewis9, Heinz Drexel10, Juan Carlos Kaski11, Dan Atar12,13, Robert F Storey14, Gregory Y H Lip15,16, Freek W A Verheugt17,18, Stefan Agewall12,13.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 26705385     DOI: 10.1093/eurheartj/ehv676

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  13 in total

Review 1.  New Oral Anticoagulants and Their Reversal Agents.

Authors:  Andrea Morotti; Joshua N Goldstein
Journal:  Curr Treat Options Neurol       Date:  2016-11       Impact factor: 3.598

2.  Time for Practical Clinical Tools.

Authors:  Demosthenes Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-08

3.  Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.

Authors:  Deborah Siegal; Genmin Lu; Janet M Leeds; Mark Karbarz; Janice Castillo; Vandana Mathur; Athiwat Hutchaleelaha; Uma Sinha; Michael Kitt; Matt McClure; Stanley J Hollenbach; John T Curnutte; Pamela B Conley; Mark Crowther
Journal:  Blood Adv       Date:  2017-09-22

4.  Management of Complications in Anticoagulated Patients with Atrial Fibrillation.

Authors:  George D Katritsis; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-12

5.  New agents for DOAC reversal: a practical management review.

Authors:  Katie White; Uzma Faruqi; Alexander Ander T Cohen
Journal:  Br J Cardiol       Date:  2022-01-12

6.  Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.

Authors:  Jennifer A Frontera; Prachi Bhatt; Rebecca Lalchan; Shadi Yaghi; Tania Ahuja; John Papadopoulos; Danielle Joset
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

Review 7.  Edoxaban in venous thromboembolism and stroke prevention: an appraisal.

Authors:  Marco Proietti; Gregory Y H Lip
Journal:  Vasc Health Risk Manag       Date:  2016-02-29

Review 8.  Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues.

Authors:  Hans-Christoph Diener; Christoph Kleinschnitz
Journal:  J Stroke       Date:  2016-05-10       Impact factor: 6.967

9.  Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.

Authors:  Genmin Lu; Polly Pine; Janet M Leeds; Francis DeGuzman; Pratikhya Pratikhya; Joyce Lin; John Malinowski; Stanley J Hollenbach; John T Curnutte; Pamela B Conley
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

Review 10.  A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment.

Authors:  M E Gimbel; S C S Minderhoud; J M Ten Berg
Journal:  Neth Heart J       Date:  2018-06       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.